Academic Journal
Blood biomarkers and Ki-67 proliferation marker in breast cancer ; Биомаркеры крови и маркер пролиферации Ki-67 при раке молочной железы
| العنوان: | Blood biomarkers and Ki-67 proliferation marker in breast cancer ; Биомаркеры крови и маркер пролиферации Ki-67 при раке молочной железы |
|---|---|
| المؤلفون: | A. A. Studenikina, E. S. Mikhaylova, S. A. Arkhipov, N. A. Varaksin, A. V. Proskura, A. I. Autenshlyus, А. А. Студеникина, Е. С. Михайлова, С. А. Архипов, Н. А. Вараксин, А. В. Проскура, А. И. Аутеншлюс |
| المساهمون: | Финансирование исследования осуществлялось за счет государственного задания Министерства здравоохранения Российской Федерации (№ АААА-А18-118030790008-7). |
| المصدر: | Medical Immunology (Russia); Том 25, № 2 (2023); 357-366 ; Медицинская иммунология; Том 25, № 2 (2023); 357-366 ; 2313-741X ; 1563-0625 |
| بيانات النشر: | SPb RAACI |
| سنة النشر: | 2023 |
| المجموعة: | Medical Immunology (E-Journal) / Медицинская иммунология |
| مصطلحات موضوعية: | рак молочной железы, proteins, Ki-67, proliferation, metastasis, breast cancer, протеины, пролиферация, метастазирование |
| الوصف: | Metastasis is the leading cause of death in patients with breast cancer (BC). It is known that the lesion of regional lymph nodes by tumor cells is more common in tumors with higher proliferative activity. Moreover, there is literature evidence on effects of cytokines and proteins upon the migration potential of the tumor. The aim of our work was to study the correlation between the concentrations of cytokines, proteins, and expression of Ki-67 proliferation marker in breast cancer with histology of non-specific invasive carcinoma.On the basis of pathological findings, 16 patients had metastases in regional lymph nodes (group I), and 18 patients had no detectable metastases (group II). Solid-phase enzyme immunoassay was used to determine concentrations of 14 cytokines in the supernatants of immunocompetent blood cells, i.e., IL-2, IL-6, IL-8, IL-10, IL-17, IL-18, IL-1β, IL-1ra, TNFα, IFNγ, G-CSF, GM-CSF, VEGF and MCP-1, and concentrations of 6 proteins were determined in blood serum: estrogen and progesterone receptors, cadherin-E (CDH1), plasminogen activator type 1 (PAI-1), mucin 1 (MUC1), heat shock protein 90αA1 (HSP90αA1). Immunohistochemical study of Ki-67 expression was performed in paraffin sections of tumors using monoclonal antibodies.The study showed that Ki-67 expression in tumor tissues and blood concentrations of IL-6, IL-8, IL-1β and TNFα were higher in group I patients. On the contrary, blood concentrations of CDH1 and PAI-1 were higher in group II patients. It was found that Ki-67 showed both inverse correlations with CDH1 and PAI1, and direct correlations with IL-8 and TNFα. CDH1 had a direct correlation with PAI1, and inverse correlations with IL-6, IL-1β and TNFα. The studied cytokines showed direct correlations with each other. The analysis of ROC curves showed good quality and optimal values of the cut-off points for Ki-67 expression, cytokine and protein concentrations, thus allowing best prediction for detectable lymphatic metastasis.On the basis of these results, a quotient was proposed, ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | Russian |
| Relation: | https://www.mimmun.ru/mimmun/article/view/2570/1652; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2570/9914; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2570/9918; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2570/9919; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2570/9921; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2570/9923; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2570/9924; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2570/9925; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2570/9926; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2570/9927; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2570/9928; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2570/9929; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2570/9947; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2570/9948; Аутеншлюс А.И., Бернадо А.В., Давлетова К.И., Архипов С.А., Жураковский И.П., Михайлова Е.С., Проскура А.В., Богачук А.П., Липкин В.М., Ляхович В.В. Белковые и иммуногистохимические маркеры заболеваний молочной железы // Биомедицинская химия, 2020. Т. 66, № 2. С. 163-173.; Давлетова К.И., Михайлова Е.С., Вараксин Н.А., Жураковский И.П., Проскура А.В., Сидоров С.В., Аутеншлюс А.И. Продукция цитокинов иммунокомпетентными клетками крови у больных инвазивной карциномой молочной железы неспецифического типа в различных возрастных группах при лимфогенном метастазировании // Медицинская иммунология, 2019. Т. 21, № 6. С. 1115-1126. doi:10.15789/1563-0625-2019-6-1115-1126.; Arafah M.A., Ouban A., Ameer O.Z., Quek K.J. KI-67 LI Expression in Triple-Negative Breast Cancer Patients and Its Significance. Breast Cancer (Auckl.), 2021, Vol. 30, no. 15, 11782234211016977. doi:10.1177/11782234211016977.; Asaoka M., Patnaik S.K., Zhang F., Ishikawa T., Takabe K. Lymphovascular invasion in breast cancer is associated with gene expression signatures of cell proliferation but not lymphangiogenesis or immune response. Breast Сancer Res. Treat., 2020, Vol. 181, no. 2, pp. 309-322.; Baram T., Rubinstein-Achiasaf L., Ben-Yaakov H., Ben-Baruch A. Inflammation-driven breast tumor cell plasticity: Stemness/EMT, therapy resistance and dormancy. Front. Oncol., 2021, Vol. 10, 614468. doi:10.3389/ fonc.2020.614468.; Ben-Baruch A. Tumor necrosis factor α: Taking a personalized road in cancer therapy. Front. Immunol., 2022, Vol. 13, 903679. doi:10.3389/fimmu.2022.903679.; Humphries B.A., Buschhaus J.M., Chen Y.C., Haley H.R., Qyli T., Chiang B., Shen N., Rajendran S., Cutter A., Cheng Y.-H., Chen Y.-T., Cong J., Spinosa P.C., Yoon E,. Luker K.E., Luker G.D. Plasminogen activator inhibitor 1 (PAI1) promotes actin cytoskeleton reorganization and glycolytic metabolism in triple-negative breast cancer. Mol. Cancer Res., 2019, Vol. 17, no. 5, pp. 1142-1154.; Lampelj M., Arko D., Cas-Sikosek N., Kavalar R., Ravnik M., Jezersek-Novakovic B., Dobnik S., Dovnik N.F., Takac I. Urokinase plasminogen activator (uPA) and plasminogen ac-tivator inhibitor type-1 (PAI-1) in breast cancer – correlation with traditional prognostic factors. Radiol. Oncol., 2015, Vol. 49, no. 4, pp. 357-364.; Liang Q., Ma D., Gao R.F., Yu K.D. Effect of Ki-67 Expression levels and histological grade on breast cancer early relapse in patients with different immunohistochemical-based subtypes. Sci. Rep., 2020, Vol. 10, no. 1, 7648. doi:10.1038/s41598-020-64523-1.; Łukaszewicz-Zając M., Pączek S., Mroczko B. The significance of chemokine CXCL-8 in esophageal carcinoma. Arch. Med. Sci., 2020, Vol. 16, no. 2, pp. 475-480.; Maranta A.F., Broder S., Fritzsche C., Knauer M., Thürlimann B., Jochum W., Ruhstaller T. Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution’s Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer. Breast, 2020, Vol. 51, pp. 120-126.; Mariotto A.B., Etzioni R., Hurlbert M., Penberthy L., Mayer M. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol. Biomark. Prev., 2017, Vol. 26, pp. 809-815.; Matutino A., Joy A.A., Brezden-Masley C., Chia S., Verma S. Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines. Curr. Oncol., 2018, Vol. 25, pp. 131-141.; Mercogliano M.F., Bruni S., Elizalde P.V., Schillaci R. Tumor necrosis factor α blockade: an opportunity to tackle breast cancer. Front. Oncol., 2020, Vol. 10, 584. doi:10.3389/fonc.2020.00584.; Narita D., Seclaman E., Anghel A., Ilina R., Cireap N., Negru S., Sirbu I.O., Ursoniu S., Marian C. Altered levels of plasma chemokines in breast cancer and their association with clinical and pathological characteristics. Neoplasma, 2016, Vol. 63, no. 1, pp. 141-149.; Petrelli F., Viale G., Cabiddu M., Barni S. Prognostic value of different cut-off levels of KI 67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res. Treat., 2015, Vol. 153, pp. 477-491.; Posso M., Corominas J.M., Serrano L., Román M., Torá-Rocamora I., Domingo L., Romero A.,Quintana M.J., Vernet-Tomas M., Baré M., Vidal C., Sánchez M., Saladié F., Natal C., Ferrer J., Servitja S., Sala M., Castells X.; BELE Study Group. Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case-control study. Cancer Med., 2017, Vol. 6, no. 6, pp. 1482-1489.; Sarode P., Schaefer M.B., Grimminger F., Seeger W., Savai R. Macrophage and tumor cell cross-talk is fundamental for lung tumor progression: we need to talk. Front. Oncol., 2020, Vol. 10, 324. doi:10.3389/ fonc.2020.00324.; Savci-Heijink C.D., Halfwerk H., Hooijer G.K.J., Koster J., Horlings H.M., Meijer S.L., van de Vijver M.J. Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior. Breast Cancer Res. Treat., 2019, Vol. 174, pp. 649-659.; Siersbæk R., Scabia V., Nagarajan S., Chernukhin I., Papachristou E.K., Broome R., Johnston S.J., Joosten S.E.P., Green A.R., Kumar S., Jones J., Omarjee S., Alvarez-Fernandez R., Glont S., Aitken S.J., Kishore K., Cheeseman D., Rakha E.A., D'Santos C., Zwart W., Russell A., Brisken C., Carroll J.S. IL6/STAT3 signaling hijacks estrogen receptor α enhancers to drive breast cancer metastasis. Cancer Сell., 2020, Vol. 38, no. 3, pp. 412-423.; Sommariva M., Gagliano N. E-Cadherin in pancreatic ductal adenocarcinoma: a multifaceted actor during EMT. Cells, 2020, Vol. 9, no. 4, 1040. doi:10.3390/cells9041040.; Völker H.U., Weigel M., Strehl A., Frey L. Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array. Diagn. Pathol., 2018, Vol. 13, no. 1, 67. doi:10.1186/s13000-018- 0737-5.; Yu P.F., Huang Y., Han Y.Y., Lin L.Y., Sun W.H., Rabson A.B., Wang Y., Shi Y.F. TNF alpha-activated mesenchymal stromal cells promote breast cancer metastasis by recruiting CXCR2 (+) neutrophils. Oncogene, 2017, Vol. 36, pp. 482-490.; Zhang S., Zhang D., Yi S., Gong M., Lu C., Cai Y., Tang X., Zou L. The relationship of lymphatic vessel density, lymphovascular invasion, and lymph node metastasis in breast cancer: a systematic review and metaanalysis. Oncotarget, 2017, Vol. 8, no. 2, pp. 2863-2873.; https://www.mimmun.ru/mimmun/article/view/2570 |
| DOI: | 10.15789/10.15789/1563-0625-BBA-2570 |
| الاتاحة: | https://www.mimmun.ru/mimmun/article/view/2570 https://doi.org/10.15789/10.15789/1563-0625-BBA-2570 |
| Rights: | Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). ; Авторы, публикующие в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License, которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном здесь виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию в этом журнале.Авторы имеют право размещать их работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access). |
| رقم الانضمام: | edsbas.3A74479F |
| قاعدة البيانات: | BASE |
| DOI: | 10.15789/10.15789/1563-0625-BBA-2570 |
|---|